SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its ...

Sutro Biopharma ( ($STRO) ) has released its Q4 earnings. Here is a breakdown of the information Sutro Biopharma presented to its investors. Sutro ...

Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate ...

Sutro Biopharma (STRO) stock falls as the company announces portfolio review, CEO appointment and headcount reduction. Read ...

An ADC tier list ranks the top champions in the bot lane, particularly those who scale their damage through items. Discover ...

Sutro Biopharma, Inc.’s STRO share price has dipped by 35.19%, which has investors questioning if this is right time to buy.

ADC Therapeutics (NYSE:ADCT – Get Free Report) is expected to be announcing its earnings results before the market opens on ...

Atria Investments Inc cut its stake in shares of Agree Realty Co. (NYSE:ADC – Free Report) by 6.2% in the fourth quarter, ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner - - Three INDs for wholly ...